Shots:
The US FDA has granted Fast Track Designation (FTD) to SOT106 for the treatment of soft tissue sarcoma
SOT106 is an ADC that targets LRRC15, a clinically validated target broadly expressed across multiple prevalent sarcoma subtypes, & has received FDA Orphan Drug Designation for osteosarcoma treatment
SOTIO plans to initiate a first-in-human clinical trial of SOT106…
